Research Reports

MS DUR Board Reports

  • 2014-08 MS-DUR Board Report – Suboxone Utilization in FFS and MSCAN
  • 2014-08 MS-DUR Board Report – Synagis 2014-15 PA criteria v7
  • 2014-08 MS-DUR Board Report – Xartemis XR criteria v5
  • 2014-08 MS-DUR Board Report – Zohydro ER criteria v5
  • 2014-08 MS-DUR Board Report – PDL Compliance Monitoring v3
  • 2014-11 MS-DUR Board Report – Metabolic Monitoring and APS v2
  • 2014-11 MS-DUR Board Report – Morphine Equivalent Dose Edit v4
  • 2014-11 MS-DUR Board Report – Oral Contraceptives and Dx v3
  • 2014-11 MS-DUR Board Report – Weight Loss Clinical Edit for Naltrexone and Bupropion v3
  • 2015-02 MS-DUR Board Report – Hepatitis C update v2
  • 2015-02 MS-DUR Board Report – Synagis update v2
  • 2015-05 MS-DUR Board Report – Concomitant Utilization of Naltrexone and Bupropion v2
  • 2015-05 MS-DUR Board Report – Diabetes Regimens v1
  • 2015-05 MS-DUR Board Report – Hysingla ER criteria v1
  • 2015-05 MS-DUR Board Report – Quality Initiative – Follow-up Children Starting ADHD Meds
  • 2015-05 MS-DUR Board Report – Quality Initiative – Metabolic Monitoring Children Antipsychotics
  • 2015-05 MS-DUR Board Report – UPDL Compliance review v2
  • 2015-07 MS-DUR Board Report – Methadone Use v6
  • 2015-07 MS-DUR Board Report – Synagis Utilizatoin 2014-15 Season v3
  • 2015-07 MS-DUR Board Report – Triazolam Utilization v5
  • 2015-10 MS-DUR Board Report – Daraprim Price Increase and Utilization v4
  • 2015-10 MS-DUR Board Report – Jadenu – Exjade Utilization and Costs V6
  • 2015-10 MS-DUR Board Report – Mental Health Medication Use in Children Transitioning from FFS to CCO V3
  • 2016-01 MS-DUR Board Report – CDC Guidelines and Opioid DUR review v4
  • 2016-01 MS-DUR Board Report – Metabolic Monitoring v4
  • 2016-01 MS-DUR Board Report – Opioid Overuse Educational Initiatives v5
  • 2016-03 MS-DUR Board Report – DUR Criteria for Managing Opioid Use and Minimizing Overdose v5
  • 2016-03 MS-DUR Board Report – Head Lice Treatment v6
  • 2016-06 MS-DUR Board Report – Preliminary Descriptives from MS-PDMP v6
  • 2016-09 MS-DUR Board Report – Benzo Utilizationa for Insomnia v4
  • 2016-09 MS-DUR Board Report – Buprenorhine-Naloxone Therapy Criteria v4
  • 2016-09 MS-DUR Board Report – Concomitant use of Benzo and Opioid v4
  • 2017-01 MS-DUR Board Report – Antidepressant Med Management in Adults v7
  • 2017-01 MS-DUR Board Report – Comparison of Pharmacy Programs v3
  • 2017-01 MS-DUR Board Report opioid provider shopping v6
  • 2017-04 MS-DUR Board Report – Citalopram Utilization and Management v5
  • 2017-04 MS-DUR Board Report – Hepatitis C Treatments 2015-2017 V3
  • 2017-04 MS-DUR Board Report – Type 2 Diabetes Treatment v6
  • 2017-07 MS-DUR Board Report – Antipsychotic use in IDD population v8
  • 2017-07 MS-DUR Board Report – Codeine Tramadol_v10
  • 2017-07 MS-DUR Board Report – Cytokine and CAM antagonist utilization v5
  • 2017-10 MS DUR Board Report – Gabapentinoid Use v9
  • 2017-10 MS-DUR Board Report – Opioid MEDD Level Trend 2016-2017 v2
  • 2017-11 MS-DUR Board Report – Codeine Tramadol update_v14
  • 2017-11 MS-DUR Board Report – Cytokine and CAM antagonist utilization v8
  • 2018-01 MS-DUR Board Report – PPI deprescribing v8
  • 2018-02 MS-DUR Board Report – PQA Diabetes Recommendations v6
  • 2018-02 MS-DUR Board Report – Stimulant and non-stimulant utilization v7
  • White Papers from MS-DUR Research Studies

  • Mental Health Medication Use Among Foster Children and Other Children Enrolled in the Mississippi Medicaid Fee-For-Service Program (July 2012)